Construction and functionalization of pyranone ring fused with pyran moiety: Design and synthesis of novel pyrano[4,3-b]pyran-5(4H)-ones as potential inhibitors of sirtuins

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 14, 2013, Pages 4195-4205

  Nakhi, Ali ^a   Shafiqur Rahman, Md ^a,b   Archana, Sivakumar ^a,c   Kishore, Ravada ^d   Seerapu, G P K ^a   Lalith Kumar, K ^a   Haldar, Devyani ^a   Pal, Manojit ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

^b UNIVERSITY OF DELHI   (India)

^c MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^d UNIVERSITY OF HYDERABAD   (India)

Author keywords

Iodocyclization; Pyranochromendione; Pyranopyranone; Sirtuins

Indexed keywords

LEAD; PYRAN DERIVATIVE; PYRANO[4,3 B]PYRAN 5(4H) ONE; SIRTUIN 2; UNCLASSIFIED DRUG;

ALKYNYLATION; ARTICLE; CATALYSIS; COVALENT BOND; CRYSTAL STRUCTURE; CYCLIZATION; DOSE RESPONSE; DRUG DESIGN; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; IODINATION; SANDMEYER REACTION; SONOGASHIRA REACTION; STRUCTURE ACTIVITY RELATION;

BINDING SITES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; ISOMERISM; MOLECULAR CONFORMATION; MOLECULAR DOCKING SIMULATION; PALLADIUM; PROTEIN BINDING; PYRANS; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SIRTUINS;

EID: 84879410137     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.05.014     Document Type: Article

References (23)

1. S. Pal, V. Chatare, and M. Pal Curr. Org. Chem. 15 2011 782
2. T. Oikawa, M. Sasaki, M. Inose, M. Shimamura, H. Kuboki, S. Hirano, H. Kumagai, M. Ishizuka, and T. Takeuchi Anticancer Res. 17 1997 1881
3. N. Mulakayala, P. VNS Murthy, D. Rambabu, M. Aeluri, R. Adepu, G.R. Krishna, C.M. Reddy, K.R.S. Prasad, M. Chaitanya, C.S. Kumar, M.V.B. Rao, and M. Pal Bioorg. Med. Chem. Lett. 22 2012 2186
4. A. Nakhi, A. Raju, D. Rambabu, R. Kishore, G.R. Vanaja, M.K. Arunasree, and M. Pal Bioorg. Med. Chem. Lett. 22 2012 4418
5. A.A. Sauve, C. Wolberger, V.L. Schramm, and J.D. Boeke Annu. Rev. Biochem. 75 2006 435
6. W. Stunkel, and R.M. Campbell J. Biomol. Screen. 16 2011 1153
7. J.C. Milne, and J.M. Denu Curr. Opin. Chem. Biol. 12 2008 11
8. A. Balcerczyk, and L. Pirola Biofactors 36 2010 383
9. B. Heltweg, T. Gatbonton, A.D. Schuler, J. Posakony, H. Li, S. Goehle, R. Kollipara, R.A. DePinho, Y. Gu, J.A. Simon, and A. Bedalov Cancer Res. 66 2006 4368
10. S. Lain, J.J. Hollick, J. Campbell, O.D. Staples, M. Higgins, M. Aoubala, A. McCarthy, V. Appleyard, K.E. Murray, L. Baker, A. Thompson, J. Mathers, S.J. Holland, M.J.R. Stark, G. Pass, J. Woods, D.P. Lane, and N.J. Westwood Cancer Cell 13 2008 454
11. J.B. Harborne Prog. Clin. Biol. Res. 280 1988 17
12. A.T. Khan, M. Lal, S. Ali, and M.Md. Khan Tetrahedron Lett. 52 2011 5327
13. M. Pal Synlett 2009 2896
14. For a review on the use of iodine as a reagent, see: M.J. Mphahlele Molecules 14 2009 5308
15. For leading references on iodocyclization, see: R. Mancuso, S. Mehta, B. Gabriele, G. Salerno, W.S. Jenks, and R.C. Larock J. Org. Chem. 75 2010 897
16. A.K. Verma, T. Aggarwal, V. Rustagi, and R.C. Larock Chem. Commun. 46 2010 4064
17. S. Mehta, and R.C. Larock J. Org. Chem. 75 2010 1652
18. C.-H. Cho, B. Neuenswander, and R.C. Larock J. Comb. Chem. 12 2010 278
19. D.K. Barange, V.R. Batchu, D. Gorja, V.R. Pattabiraman, L.K. Tatini, J.M. Babu, and M. Pal Tetrahedron 63 2007 1775
20. M. Layek, Y.S. Kumar, A. Islam, R. Karavarapu, A. Sengupta, D. Halder, K. Mukkanti, and M. Pal Med. Chem. Commun. 2 2011 478
21. Splitomicin has been reported to inhibit yeast sir2 with an IC50 value of 60 μM in vitro, see: A. Bedalov, T. Gatbonton, W.P. Irvine, D.E. Gottschling, and J.A. Simon Proc. Natl. Acad. Sci. U.S.A. 98 2001 15113
22. C.M. Grozinger, E.D. Chao, H.E. Blackwell, D. Moazed, and S.L. Schreiber J. Biol. Chem. 276 2001 38837
23. Hall, B. E.; Buchberger, J. R.; Gerber, S. A.; Ambrosio, A. L. B.; Gygi, S. P.; Filman, D.; Moazed, D.; Ellenberger, T. doi: http://www.rcsb.org/pdb/ explore/explore.do?structureId=2hjh.